SPY411.45-1.41 -0.34%
DIA337.53+0.74 0.22%
IXIC13,857.84-138.26 -0.99%

BRIEF-Medicago And GSK Start Phase 3 Trial Of Adjuvanted COVID-19 Vaccine Candidate

· 03/16/2021 07:00
BRIEF-Medicago And GSK Start Phase 3 Trial Of Adjuvanted COVID-19 Vaccine Candidate

- MEDICAGO:

  • MEDICAGO AND GSK START PHASE 3 TRIAL OF ADJUVANTED COVID-19 VACCINE CANDIDATE

  • MEDICAGO - PHASE 2 PORTION OF COVID-19 VACCINE CANDIDATE TRIAL APPROACHING COMPLETION & RESULTS EXPECTED TO BE MADE PUBLICLYAVAILABLE IN APRIL 2021

  • MEDICAGO - PHASE 3 TRIAL OF COVID-19 VACCINE CANDIDATE TO ENROLL UP TO 30,000 VOLUNTEERS WORLDWIDE

  • MEDICAGO - INITIATED A FEASIBILITY STUDY OF A VACCINE CANDIDATE TO ADDRESS THE EMERGING COVID-19 VARIANTS

Source text for Eikon: ID:nBwcb65z5a


((Reuters.Briefs@thomsonreuters.com;))